kw.\*:("Sunitinib (SU11248; SUTENT®), Tyrosine kinase inhibitors")
Results 1 to 1 of 1
Selection :
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodBRITTEN, Carolyn D; KABBINAVAR, Fairooz; HECHT, J. Randolph et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 3, pp 515-524, issn 0344-5704, 10 p.Article
